Similarly, CDK7 inhibition supress the growth of GRP56+ LICs and CDK7 inhibitors synergize with venetoclax in inhibiting the in vitro and in vivo growth of AML cells [46]. The gene discussed is CDK7; the disease is acute myeloid leukemia.